Pfizer‘s better-than-expected earnings report wasn’t enough to blow away the gloom that has settled over the stock, but shares rose on the CEO’s optimism that anticipated drug tariff’s won’t have a ...

Shares in Pfizer ($PFE) inched higher early Tuesday even as the U.S. pharma giant forecast 2026 earnings that are below Wall ...

Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, ...

Amid profit forecast reductions, Pfizer is implementing a $7.7bn cost-cutting strategy, while investing into its ...

Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...